Philip Morris Seeks FDA MRTP Label for ZYN Pouches to Reduce Six Disease Risks
Philip Morris International presented scientific evidence to the FDA’s Tobacco Products Scientific Advisory Committee on January 22, seeking an MRTP label for its ZYN nicotine pouches, aiming to claim reduced risks for six smoking-linked diseases. FDA documents note the proposed claims are scientifically accurate, and PM shares rose 1.09% post-announcement.
1. First Citizens Bank & Trust Co. Reduces Philip Morris Stake
First Citizens Bank & Trust Co. trimmed its position in Philip Morris International by 12.3% during the third quarter, selling 6,120 shares and ending the period with 43,799 shares. According to its most recent Form 13F filing, the remaining stake was valued at $7.104 million as of the quarter’s end, reflecting the fund’s strategic rebalancing of its equity portfolio.
2. Other Institutional Investors Adjust Positions
Several smaller funds made notable moves in the quarter. Legacy Investment Solutions LLC and Traub Capital Management LLC each initiated positions worth approximately $25,000. Marquette Asset Management LLC boosted its holding by 1,677.8%, purchasing an additional 151 shares to reach 160 shares valued at $26,000. Briaud Financial Planning Inc. raised its stake to 165 shares—up 266.7%—representing $30,000 in market value, while Estabrook Capital Management also established a new $30,000 position. Institutional investors now account for 78.63% of outstanding shares.
3. Dividend Policy and Payout Metrics
Philip Morris International declared its latest quarterly dividend at $1.47 per share, with an ex-dividend date of December 26 and payment issued on January 14 to shareholders of record on the ex-dividend date. This distribution annualizes to $5.88 per share, yielding 3.4% based on current equity value, and results in a payout ratio of 106.52%, underscoring the company’s commitment to returning capital despite high coverage demands.
4. Valuation Overview and Analyst Sentiment
The company carries a market capitalization of $269.39 billion, a price-to-earnings ratio of 31.35, a price-to-earnings-growth ratio of 1.86 and a beta of 0.40. Its 50-day and 200-day moving averages stand at $159.22 and $161.48 respectively. Among sell-side analysts, 11 maintain Buy ratings and two hold ratings, with an average price target of $184.56, reflecting a consensus of moderate upside potential driven by stable cash flows and growth in smoke-free product segments.